<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="23.12.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="0" size="9" family="HIOGBN+AdvOT56309c18.I" color="#10157e"/>
	<fontspec id="1" size="9" family="HIOFBI+AdvOT46dcae81" color="#000000"/>
	<fontspec id="2" size="9" family="HIOGBO+AdvOT65f8a23b.I" color="#000000"/>
	<fontspec id="3" size="6" family="HIOFBI+AdvOT46dcae81" color="#000080"/>
	<fontspec id="4" size="9" family="HIOFHL+AdvOT3b30f6db.B" color="#000000"/>
	<fontspec id="5" size="6" family="HIOFBI+AdvOT46dcae81" color="#000000"/>
	<fontspec id="6" size="9" family="HIOFBI+AdvOT46dcae81" color="#000080"/>
	<fontspec id="7" size="9" family="HIOGBP+AdvPSMP13" color="#000000"/>
	<fontspec id="8" size="9" family="HIOGCP+AdvP4C4E51" color="#000000"/>
	<fontspec id="9" size="9" family="HIOFHM+AdvOT46dcae81+20" color="#000000"/>
	<fontspec id="10" size="9" family="HIOFFI+AdvP4C4E74" color="#000000"/>
	<fontspec id="11" size="6" family="HIOFFI+AdvP4C4E74" color="#000000"/>
	<fontspec id="12" size="8" family="HIOFHO+AdvOTc20ddc96" color="#10157e"/>
	<fontspec id="13" size="8" family="HIOFHJ+AdvOT5fcf1b24" color="#000000"/>
	<fontspec id="14" size="7" family="HIOHHI+Arial" color="#231f20"/>
	<fontspec id="15" size="8" family="HIOHHJ+Arial" color="#231f20"/>
	<fontspec id="16" size="7" family="HIOFBI+AdvOT46dcae81" color="#000000"/>
<text top="417" left="42" width="163" height="10" font="0">Cat K inhibitors based on ketone warhead</text>
<text top="428" left="42" width="57" height="8" font="1">In 1997, Veber</text>
<text top="428" left="103" width="19" height="8" font="2">et al.</text>
<text top="428" left="127" width="173" height="8" font="1">reported a series of selective and reversible</text>
<text top="439" left="42" width="258" height="8" font="1">Cat K inhibitors based on a poorly electrophilic 1,3-bis(acylamino)-</text>
<text top="450" left="42" width="85" height="8" font="1">2-propanone scaffold</text>
<text top="448" left="127" width="7" height="5" font="3"><a href="">19</a></text>
<text top="450" left="134" width="166" height="8" font="1"><a href="">. </a>Through modelling the interaction of</text>
<text top="462" left="42" width="258" height="8" font="1">active-sites and simplifying the structure of inhibitors, they devel-</text>
<text top="473" left="42" width="157" height="8" font="1">oped an accessible symmetrical ketone</text>
<text top="473" left="204" width="5" height="8" font="4">1</text>
<text top="473" left="214" width="26" height="8" font="1">with a</text>
<text top="473" left="244" width="5" height="8" font="2">K</text>
<text top="477" left="249" width="14" height="5" font="5">i,app</text>
<text top="473" left="268" width="32" height="8" font="1">value of</text>
<text top="484" left="42" width="87" height="8" font="1">22 nM against Cat K (</text>
<text top="484" left="129" width="33" height="8" font="6"><a href="">Figure 3</a></text>
<text top="484" left="161" width="130" height="8" font="1">). It was interesting to note that</text>
<text top="484" left="295" width="5" height="8" font="4">1</text>
<text top="495" left="42" width="258" height="8" font="1">exhibited excellent selectivity over other members of cathepsin</text>
<text top="507" left="42" width="31" height="8" font="1">family (</text>
<text top="507" left="73" width="5" height="8" font="2">K</text>
<text top="510" left="77" width="14" height="5" font="5">i,app</text>
<text top="507" left="96" width="101" height="8" font="1">cathepsin L (Cat L), 0.34</text>
<text top="505" left="199" width="5" height="12" font="7">l</text>
<text top="507" left="204" width="96" height="8" font="1">M; cathepsin B (Cat B),</text>
<text top="518" left="42" width="11" height="8" font="1">1.3</text>
<text top="516" left="55" width="5" height="12" font="7">l</text>
<text top="518" left="60" width="104" height="8" font="1">M; cathepsin S (Cat S), 0.89</text>
<text top="516" left="165" width="5" height="12" font="7">l</text>
<text top="518" left="170" width="10" height="8" font="1"><a href="">M)</a></text>
<text top="516" left="180" width="7" height="5" font="3"><a href="">20</a></text>
<text top="518" left="187" width="79" height="8" font="1">. N-methyl analog of</text>
<text top="518" left="269" width="5" height="8" font="4">1</text>
<text top="518" left="277" width="23" height="8" font="1">exam-</text>
<text top="529" left="42" width="138" height="8" font="1">ined effects of methylation, ketone</text>
<text top="529" left="184" width="5" height="8" font="4">2</text>
<text top="529" left="189" width="111" height="8" font="1">, was 4-fold less active than</text>
<text top="541" left="42" width="5" height="8" font="4">1</text>
<text top="541" left="47" width="253" height="8" font="1">. Whereas, in order to span the distance of both sides of its</text>
<text top="552" left="42" width="228" height="8" font="1">active site (picking up the Trp184 aromatic interaction)</text>
<text top="552" left="275" width="5" height="8" font="4">3</text>
<text top="552" left="280" width="20" height="8" font="1">, the</text>
<text top="563" left="42" width="120" height="8" font="1">chemical moiety of Cbz-Leu in</text>
<text top="563" left="166" width="5" height="8" font="4">1</text>
<text top="563" left="174" width="126" height="8" font="1">substituted by 4-phenoxyphenyl</text>
<text top="574" left="42" width="258" height="8" font="1">sulfonamide, showed 10-fold more active than their original pep-</text>
<text top="586" left="42" width="61" height="8" font="1">tide-based lead.</text>
<text top="597" left="54" width="246" height="8" font="1">On the other hand, extension of aromatic moiety interacted</text>
<text top="608" left="42" width="82" height="8" font="1">with Try67, DesJarlais</text>
<text top="608" left="127" width="19" height="8" font="2">et al.</text>
<text top="606" left="146" width="7" height="5" font="3"><a href="">21</a></text>
<text top="608" left="156" width="144" height="8" font="1">developed a variety of sulfonyl inhib-</text>
<text top="619" left="42" width="79" height="8" font="1">itors, among which</text>
<text top="619" left="127" width="5" height="8" font="4">4</text>
<text top="619" left="137" width="163" height="8" font="1">with the biphenyl group replacing Cbz</text>
<text top="631" left="42" width="224" height="8" font="1">showed greater than 500-fold selectivity over Cat B, S, L (</text>
<text top="631" left="266" width="5" height="8" font="2">K</text>
<text top="634" left="270" width="14" height="5" font="5">i,app</text>
<text top="631" left="287" width="12" height="8" font="1">Cat</text>
<text top="642" left="42" width="68" height="8" font="1">K, 1.4 nM; Cat B,</text>
<text top="640" left="115" width="7" height="12" font="8">&gt;</text>
<text top="642" left="122" width="131" height="8" font="1">10000 nM; Cat S, 910 nM; Cat L,</text>
<text top="640" left="258" width="7" height="12" font="8">&gt;</text>
<text top="642" left="265" width="35" height="8" font="1">1000 nM)</text>
<text top="653" left="42" width="3" height="8" font="1">(</text>
<text top="653" left="45" width="33" height="8" font="6"><a href="">Figure 3</a></text>
<text top="653" left="78" width="222" height="8" font="1"><a href="">). </a>The biphenyl group that best matched the conform-</text>
<text top="664" left="42" width="258" height="8" font="1">ation of prime side is more rigid and bulky than the benzyl carba-</text>
<text top="676" left="42" width="258" height="8" font="1">mate. From the analysis of X-ray co-crystal structure, the biphenyl</text>
<text top="687" left="42" width="37" height="8" font="1">system in</text>
<text top="687" left="83" width="5" height="8" font="4">4</text>
<text top="687" left="92" width="208" height="8" font="1">occupied the S3 site rather than the substrate back-</text>
<text top="698" left="42" width="175" height="8" font="1">bone binding site and formed an aromatic</text>
<text top="696" left="217" width="4" height="12" font="9">–</text>
<text top="698" left="221" width="79" height="8" font="1">aromatic interaction</text>
<text top="710" left="42" width="42" height="8" font="1">with Tyr67.</text>
<text top="721" left="54" width="30" height="8" font="1">Marquis</text>
<text top="721" left="88" width="20" height="8" font="2">et al.</text>
<text top="719" left="108" width="7" height="5" font="3"><a href="">22</a></text>
<text top="721" left="119" width="181" height="8" font="1">designed an azepanone-basediInhibitor of Cat</text>
<text top="732" left="42" width="5" height="8" font="1">K</text>
<text top="732" left="50" width="5" height="8" font="4">5</text>
<text top="732" left="55" width="245" height="8" font="1">, which possessed some special structures including a C-4 chiral</text>
<text top="743" left="42" width="258" height="8" font="1">center as S and an azepanone ring in a pseudo-boat conformation</text>
<text top="257" left="312" width="3" height="8" font="1">(</text>
<text top="257" left="315" width="32" height="8" font="6"><a href="">Figure 3</a></text>
<text top="257" left="347" width="223" height="8" font="1"><a href="">). </a>The C-4 S stereochemistry was critical for potent inhib-</text>
<text top="268" left="312" width="258" height="8" font="1">ition that predicted the higher energy axial orientation bound</text>
<text top="279" left="312" width="258" height="8" font="1">within the active site of Cat K by molecular modelling. Compound</text>
<text top="290" left="312" width="5" height="8" font="4">5</text>
<text top="290" left="317" width="253" height="8" font="1">, which incorporated the replacement of the carbonylbenzyloxy</text>
<text top="301" left="312" width="258" height="8" font="1">group with the benzofuran-2-carboxyamide showed a potently</text>
<text top="312" left="312" width="164" height="8" font="1">reversible inhibitor of human Cat K with a</text>
<text top="312" left="479" width="5" height="8" font="2">K</text>
<text top="316" left="484" width="2" height="5" font="5">i</text>
<text top="310" left="487" width="7" height="12" font="10">¼</text>
<text top="312" left="496" width="74" height="8" font="1">0.16 nM and a rela-</text>
<text top="323" left="312" width="182" height="8" font="1">tively acceptable selectivity against Cat B, S, L (</text>
<text top="323" left="494" width="5" height="8" font="2">K</text>
<text top="327" left="499" width="14" height="5" font="5">i,app</text>
<text top="323" left="515" width="55" height="8" font="1">Cat B, 500 nM;</text>
<text top="334" left="312" width="258" height="8" font="1">Cat S, 4 nM; Cat L, 2.2 nM). Comparison of the transport of cyclic</text>
<text top="345" left="312" width="258" height="8" font="1">and acyclic analogs, the results from pharmacokinetic analysis</text>
<text top="356" left="312" width="68" height="8" font="1">revealed inhibitor</text>
<text top="356" left="383" width="5" height="8" font="4">5</text>
<text top="356" left="391" width="179" height="8" font="1">with cyclic has good oral bioavailability in the</text>
<text top="367" left="312" width="67" height="8" font="1">rat of 42% with a</text>
<text top="367" left="382" width="4" height="8" font="2">T</text>
<text top="371" left="386" width="9" height="5" font="5">1/2</text>
<text top="367" left="398" width="38" height="8" font="1">of 30 min.</text>
<text top="378" left="324" width="246" height="8" font="1">The ketone inhibitors of Cat K pioneered by GSK scientists have</text>
<text top="389" left="312" width="258" height="8" font="1">been taken a huge number of efforts to realise the desired inhib-</text>
<text top="400" left="312" width="156" height="8" font="1">ition and selectivity. The discovery of</text>
<text top="400" left="473" width="5" height="8" font="4">6</text>
<text top="400" left="484" width="86" height="8" font="1">embodying extremely</text>
<text top="412" left="312" width="258" height="8" font="1">potent inhibition with picomolar affinity, known as relacatib or</text>
<text top="423" left="312" width="258" height="8" font="1">SB-462795 (Developed by GSK), was considered as an important</text>
<text top="434" left="312" width="44" height="8" font="1">milestone (</text>
<text top="434" left="356" width="33" height="8" font="6"><a href="">Figure 3</a></text>
<text top="434" left="388" width="3" height="8" font="1">)</text>
<text top="432" left="391" width="7" height="5" font="3"><a href="">23</a></text>
<text top="434" left="398" width="49" height="8" font="1"><a href="">. </a>Compound</text>
<text top="434" left="451" width="5" height="8" font="4">6</text>
<text top="434" left="460" width="110" height="8" font="1">in a chair conformation has</text>
<text top="445" left="312" width="256" height="8" font="1">an axial methyl group at C-7 position, which contacts with the S1</text>
<text top="442" left="568" width="2" height="8" font="11">0</text>
<text top="456" left="312" width="258" height="8" font="1">hydrophobic pocket, while the sulfonylpyridine interacts with the</text>
<text top="467" left="312" width="9" height="8" font="1">S2</text>
<text top="464" left="321" width="2" height="8" font="11">0</text>
<text top="467" left="328" width="232" height="8" font="1">hydrophobic pocket. The interactions between compound</text>
<text top="467" left="565" width="5" height="8" font="4">6</text>
<text top="478" left="312" width="101" height="8" font="1">and Cat K are shown in</text>
<text top="478" left="418" width="34" height="8" font="6"><a href="">Figure 4</a></text>
<text top="478" left="451" width="119" height="8" font="1">. Furthermore, conformational</text>
<text top="489" left="312" width="258" height="8" font="1">analysis revealed that the methyl group at C-4 increased the con-</text>
<text top="500" left="312" width="258" height="8" font="1">figurational stability. The 7-methyl substituted azepanone analog</text>
<text top="511" left="312" width="258" height="8" font="1">shows favorable pharmacokinetic characteristics, good oral bio-</text>
<text top="522" left="312" width="98" height="8" font="1">availability (89%), and an</text>
<text top="522" left="414" width="25" height="8" font="2">in vivo</text>
<text top="522" left="443" width="127" height="8" font="1">clearance rate of 19.5 ml/min/kg.</text>
<text top="533" left="312" width="205" height="8" font="1">However, in spite of those advantages, compound</text>
<text top="533" left="522" width="5" height="8" font="4">6</text>
<text top="533" left="531" width="39" height="8" font="1">exhibits a</text>
<text top="544" left="312" width="240" height="8" font="1">rather low or no selectivity over other off-target cathepsins (</text>
<text top="544" left="552" width="5" height="8" font="2">K</text>
<text top="548" left="556" width="14" height="5" font="5">i,app</text>
<text top="555" left="312" width="258" height="8" font="1">Cat K, 0.041 nM; Cat L, 0.068 nM; cathepsin V (Cat V), 0.053 nM; Cat</text>
<text top="566" left="312" width="89" height="8" font="1">B, 15 nM; Cat S, 1.6 <a href="">nM)</a></text>
<text top="564" left="401" width="7" height="5" font="3"><a href="">24</a></text>
<text top="566" left="408" width="2" height="8" font="1">.</text>
<text top="577" left="324" width="193" height="8" font="1">During the systemic research of odanacatib, Boyd</text>
<text top="577" left="520" width="19" height="8" font="2">et al.</text>
<text top="577" left="543" width="27" height="8" font="1">investi-</text>
<text top="588" left="312" width="258" height="8" font="1">gated that the replacement of nitrile with cyclic ketone warheads</text>
<text top="599" left="312" width="258" height="8" font="1">was based on the experience of ketones as reversible Cat K</text>
<text top="611" left="312" width="36" height="8" font="1">inhibitors</text>
<text top="609" left="348" width="3" height="5" font="3"><a href="">8</a></text>
<text top="609" left="351" width="1" height="5" font="5">,</text>
<text top="609" left="353" width="7" height="5" font="3"><a href="">25</a></text>
<text top="611" left="360" width="210" height="8" font="1"><a href="">. </a>Substitution of the benzofuran moiety of compound</text>
<text top="622" left="312" width="5" height="8" font="4">5</text>
<text top="622" left="323" width="247" height="8" font="1">with an odanacatib-like 4-methylsulfonylphenyl backbone, to</text>
<text top="633" left="312" width="76" height="8" font="1">provide compound</text>
<text top="633" left="394" width="5" height="8" font="4">7</text>
<text top="633" left="399" width="171" height="8" font="1">, conceivably allowed interactions on the</text>
<text top="644" left="312" width="41" height="8" font="1">prime side</text>
<text top="642" left="353" width="7" height="5" font="3"><a href="">26</a></text>
<text top="644" left="359" width="210" height="8" font="1">. The biphenyl of the substrate intensively participates</text>
<text top="655" left="312" width="258" height="8" font="1">a ring-ring interaction between Tyr67 at the S3 pocket. In spite of</text>
<text top="666" left="312" width="62" height="8" font="1">this, compound</text>
<text top="666" left="379" width="5" height="8" font="4">7</text>
<text top="666" left="388" width="182" height="8" font="1">only furnished improved partial selectivity as</text>
<text top="677" left="312" width="174" height="8" font="1">well as more than 10-fold reduced inhibition.</text>
<text top="688" left="324" width="246" height="8" font="1">Merck Frost also provided a series of ketone inhibitors of vari-</text>
<text top="699" left="312" width="258" height="8" font="1">ous cyclic aminoketone ring size and nitrogen substitution, such</text>
<text top="710" left="312" width="8" height="8" font="1">as</text>
<text top="710" left="323" width="5" height="8" font="4">8</text>
<text top="710" left="328" width="2" height="8" font="1">,</text>
<text top="710" left="334" width="5" height="8" font="4">9</text>
<text top="710" left="343" width="3" height="8" font="1"><a href="">(</a></text>
<text top="710" left="345" width="32" height="8" font="6"><a href="">Figure 3</a></text>
<text top="710" left="377" width="3" height="8" font="1">)</text>
<text top="708" left="380" width="7" height="5" font="3"><a href="">27</a></text>
<text top="710" left="387" width="30" height="8" font="1"><a href="">. </a>The IC</text>
<text top="714" left="417" width="7" height="5" font="5">50</text>
<text top="710" left="428" width="142" height="8" font="1">values against humanised rabbit Cat</text>
<text top="721" left="312" width="258" height="8" font="1">K and selectivity against human Cat L, B, and S exhibited no sig-</text>
<text top="732" left="312" width="173" height="8" font="1">nificant difference compared with inhibitor</text>
<text top="732" left="490" width="5" height="8" font="4"><a href="">7</a></text>
<text top="730" left="495" width="7" height="5" font="3"><a href="">28</a></text>
<text top="732" left="502" width="68" height="8" font="1">. Moreover, from</text>
<text top="743" left="312" width="258" height="8" font="1">the rat bile cannulation study, these inhibitors were rapidly cleared</text>
<text top="223" left="42" width="29" height="9" font="12">Figure 1.</text>
<text top="225" left="75" width="495" height="7" font="13">Ribbon drawing of human Cat K and the active sites of Cat K. (A) The overall ribbon structure of human Cat K. The structure is from Protein Data Bank (PDB</text>
<text top="234" left="42" width="179" height="7" font="13">ID: 5TDI). (B) The residues in active sites of human Cat K.</text>
<text top="319" left="136" width="5" height="8" font="14">N</text>
<text top="297" left="123" width="5" height="8" font="14">O</text>
<text top="306" left="176" width="5" height="8" font="14">H</text>
<text top="312" left="176" width="5" height="8" font="14">N</text>
<text top="297" left="150" width="5" height="8" font="14">R</text>
<text top="335" left="163" width="5" height="8" font="14">O</text>
<text top="335" left="190" width="9" height="8" font="14">P1</text>
<text top="312" left="203" width="5" height="8" font="14">E</text>
<text top="282" left="203" width="5" height="8" font="14">S</text>
<text top="330" left="231" width="22" height="8" font="14">P1'-P2'</text>
<text top="259" left="216" width="25" height="8" font="14">Enzyme</text>
<text top="272" left="176" width="22" height="8" font="14">Cys 25</text>
<text top="335" left="136" width="5" height="8" font="14">H</text>
<text top="351" left="145" width="20" height="8" font="14">Gly 66</text>
<text top="344" left="58" width="10" height="10" font="15"><b>S3</b></text>
<text top="262" left="148" width="10" height="10" font="15"><b>S2</b></text>
<text top="378" left="190" width="10" height="10" font="15"><b>S1</b></text>
<text top="376" left="258" width="26" height="10" font="15"><b>S1'-S2'</b></text>
<text top="345" left="241" width="24" height="8" font="14">Trp 184</text>
<text top="282" left="237" width="21" height="8" font="14">Gln 19</text>
<text top="360" left="89" width="20" height="8" font="14">Tyr 67</text>
<text top="292" left="84" width="22" height="8" font="14">Asp 61</text>
<text top="349" left="117" width="25" height="8" font="14">Leu 205</text>
<text top="364" left="214" width="26" height="8" font="14">Asn 175</text>
<text top="367" left="155" width="24" height="8" font="14">His 159</text>
<text top="391" left="42" width="29" height="9" font="12">Figure 2.</text>
<text top="393" left="75" width="139" height="7" font="13">Key binding features of active sites in Cat K.</text>
<text top="28" left="335" width="201" height="7" font="16">JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY</text>
<text top="28" left="558" width="12" height="7" font="16">891</text>
</page>
</pdf2xml>
